{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,4]],"date-time":"2026-11-04T22:27:19Z","timestamp":1793831239069,"version":"4.6.1"},"reference-count":31,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"name":"Hunan Provincial Key Laboratory of the Traditional Chinese Medicine Agricultural Biogenomics"},{"DOI":"10.13039\/501100004735","name":"Natural Science Foundation of Hunan Province","doi-asserted-by":"publisher","award":["2023JJ30847"],"award-info":[{"award-number":["2023JJ30847"]}],"id":[{"id":"10.13039\/501100004735","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Invest New Drugs"],"published-print":{"date-parts":[[2025,8]]},"DOI":"10.1007\/s10637-025-01575-y","type":"journal-article","created":{"date-parts":[[2025,8,13]],"date-time":"2025-08-13T08:27:38Z","timestamp":1755073658000},"page":"885-893","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Clinical characteristics, treatment and prognosis of pembrolizumab induced myocarditis"],"prefix":"10.1007","volume":"43","author":[{"given":"Zhaoquan","family":"Wu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chunjiang","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,8,13]]},"reference":[{"issue":"11","key":"1575_CR1","doi-asserted-by":"publisher","first-page":"2777","DOI":"10.1080\/21645515.2016.1199310","volume":"12","author":"G Kwok","year":"2016","unstructured":"Kwok G, Yau TC, Chiu JW, Tse E, Kwong YL (2016) Pembrolizumab (Keytruda). Hum Vaccin Immunother 12(11):2777\u20132789. https:\/\/doi.org\/10.1080\/21645515.2016.1199310","journal-title":"Hum Vaccin Immunother"},{"issue":"2","key":"1575_CR2","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1111\/cei.13060","volume":"191","author":"SM Toor","year":"2018","unstructured":"Toor SM, Syed Khaja AS, Alkurd I, Elkord E (2018) In-vitro effect of pembrolizumab on different T regulatory cell subsets. Clin Exp Immunol 191(2):189\u2013197. https:\/\/doi.org\/10.1111\/cei.13060","journal-title":"Clin Exp Immunol"},{"issue":"10027","key":"1575_CR3","doi-asserted-by":"publisher","first-page":"1540","DOI":"10.1016\/S0140-6736(15)01281-7","volume":"387","author":"RS Herbst","year":"2016","unstructured":"Herbst RS, Baas P, Kim DW, Felip E, P\u00e9rez-Gracia JL, Han JY et al (2016) Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial. Lancet 387(10027):1540\u20131550. https:\/\/doi.org\/10.1016\/S0140-6736(15)01281-7","journal-title":"Lancet"},{"issue":"21","key":"1575_CR4","doi-asserted-by":"publisher","first-page":"2018","DOI":"10.1056\/NEJMoa1501824","volume":"372","author":"EB Garon","year":"2015","unstructured":"Garon EB, Rizvi NA, Hui R, Leighl N, Balmanoukian AS, Eder JP et al (2015) Pembrolizumab for the treatment of non-small-cell lung cancer. N Engl J Med 372(21):2018\u20132028. https:\/\/doi.org\/10.1056\/NEJMoa1501824","journal-title":"N Engl J Med"},{"issue":"1","key":"1575_CR5","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1080\/13548500802537903","volume":"14","author":"C Abraham","year":"2009","unstructured":"Abraham C, Kelly MP, West R, Michie S (2009) The UK National Institute for Health and Clinical Excellence public health guidance on behaviour change: a brief introduction. Psychol Health Med 14(1):1\u20138","journal-title":"Psychol Health Med"},{"issue":"36","key":"1575_CR6","doi-asserted-by":"publisher","first-page":"4073","DOI":"10.1200\/JCO.21.01440","volume":"39","author":"BJ Schneider","year":"2021","unstructured":"Schneider BJ, Naidoo J, Santomasso BD, Lacchetti C, Adkins S, Anadkat M et al (2021) Management of immune-related adverse events in patients treated with immune checkpoint inhibitor therapy: ASCO guideline update. J Clin Oncol 39(36):4073\u20134126. https:\/\/doi.org\/10.1200\/JCO.21.01440","journal-title":"J Clin Oncol"},{"issue":"13","key":"1575_CR7","doi-asserted-by":"publisher","first-page":"1714","DOI":"10.1016\/j.jacc.2019.07.079","volume":"74","author":"S Ball","year":"2019","unstructured":"Ball S, Ghosh RK, Wongsaengsak S, Bandyopadhyay D, Ghosh GC, Aronow WS et al (2019) Cardiovascular Toxicities of Immune Checkpoint Inhibitors: JACC Review Topic of the Week. J Am Coll Cardiol 74(13):1714\u20131727. https:\/\/doi.org\/10.1016\/j.jacc.2019.07.079","journal-title":"J Am Coll Cardiol"},{"issue":"18","key":"1575_CR8","doi-asserted-by":"publisher","first-page":"1749","DOI":"10.1056\/NEJMoa1609214","volume":"375","author":"DB Johnson","year":"2016","unstructured":"Johnson DB, Balko JM, Compton ML, Chalkias S, Gorham J, Xu Y et al (2016) Fulminant myocarditis with combination immune checkpoint blockade. N Engl J Med 375(18):1749\u20131755. https:\/\/doi.org\/10.1056\/NEJMoa1609214","journal-title":"N Engl J Med"},{"issue":"16","key":"1575_CR9","doi-asserted-by":"publisher","first-page":"1755","DOI":"10.1016\/j.jacc.2018.02.037","volume":"71","author":"SS Mahmood","year":"2018","unstructured":"Mahmood SS, Fradley MG, Cohen JV, Nohria A, Reynolds KL, Heinzerling LM et al (2018) Myocarditis in patients treated with immune checkpoint inhibitors. J Am Coll Cardiol 71(16):1755\u20131764. https:\/\/doi.org\/10.1016\/j.jacc.2018.02.037","journal-title":"J Am Coll Cardiol"},{"issue":"4","key":"1575_CR10","doi-asserted-by":"publisher","first-page":"e000247","DOI":"10.1136\/esmoopen-2017-000247","volume":"2","author":"G Varricchi","year":"2017","unstructured":"Varricchi G, Galdiero MR, Marone G, Criscuolo G, Triassi M, Bonaduce D, Marone G, Tocchetti CG (2017) Cardiotoxicity of immune checkpoint inhibitors. ESMO Open 2(4):e000247. https:\/\/doi.org\/10.1136\/esmoopen-2017-000247","journal-title":"ESMO Open"},{"issue":"1","key":"1575_CR11","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1186\/s12885-020-07741-0","volume":"21","author":"R Ma","year":"2021","unstructured":"Ma R, Wang Q, Meng D, Li K, Zhang Y (2021) Immune checkpoint inhibitors-related myocarditis in patients with cancer: an analysis of international spontaneous reporting systems. BMC Cancer 21(1):38. https:\/\/doi.org\/10.1186\/s12885-020-07741-0","journal-title":"BMC Cancer"},{"issue":"5","key":"1575_CR12","doi-asserted-by":"publisher","first-page":"e145186","DOI":"10.1172\/JCI145186","volume":"131","author":"J Moslehi","year":"2021","unstructured":"Moslehi J, Lichtman AH, Sharpe AH, Galluzzi L, Kitsis RN (2021) Immune checkpoint inhibitor-associated myocarditis: manifestations and mechanisms. J Clin Invest 131(5):e145186. https:\/\/doi.org\/10.1172\/JCI145186","journal-title":"J Clin Invest"},{"issue":"3","key":"1575_CR13","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1007\/s11886-017-0835-0","volume":"19","author":"DY Wang","year":"2017","unstructured":"Wang DY, Okoye GD, Neilan TG, Johnson DB, Moslehi JJ (2017) Cardiovascular toxicities associated with cancer immunotherapies. Curr Cardiol Rep 19(3):21. https:\/\/doi.org\/10.1007\/s11886-017-0835-0","journal-title":"Curr Cardiol Rep"},{"issue":"7","key":"1575_CR14","doi-asserted-by":"publisher","first-page":"651","DOI":"10.1016\/j.cjco.2022.03.007","volume":"4","author":"T Nishikawa","year":"2022","unstructured":"Nishikawa T, Tamiya M, Ohta-Ogo K, Ikeda Y, Hatakeyama K, Honma K, Yasui T, Shioyama W, Oka T, Inoue T, Kumagai T, Fujita M (2022) A case of lung cancer with very-late-onset immune checkpoint inhibitor-related myocarditis. CJC Open 4(7):651\u2013655. https:\/\/doi.org\/10.1016\/j.cjco.2022.03.007","journal-title":"CJC Open"},{"issue":"11","key":"1575_CR15","doi-asserted-by":"publisher","first-page":"1168","DOI":"10.1007\/s12012-024-09906-w","volume":"24","author":"A Villatore","year":"2024","unstructured":"Villatore A, Bosi C, Pomaranzi C, Cigliola A, Tateo V, Mercinelli C, Vignale D, Rizzo S, Necchi A, Peretto G (2024) Myocarditis following Pembrolizumab plus Axitinib, and Belzutifan plus Lenvatinib for renal cell carcinoma: a case report. Cardiovasc Toxicol 24(11):1168\u20131173. https:\/\/doi.org\/10.1007\/s12012-024-09906-w","journal-title":"Cardiovasc Toxicol"},{"issue":"7","key":"1575_CR16","doi-asserted-by":"publisher","first-page":"917","DOI":"10.1016\/j.annonc.2021.03.204","volume":"32","author":"CN Owen","year":"2021","unstructured":"Owen CN, Bai X, Quah T, Lo SN, Allayous C, Callaghan S et al (2021) Delayed immune-related adverse events with anti-PD-1-based immunotherapy in melanoma. Ann Oncol 32(7):917\u2013925. https:\/\/doi.org\/10.1016\/j.annonc.2021.03.204","journal-title":"Ann Oncol"},{"issue":"19","key":"1575_CR17","doi-asserted-by":"publisher","first-page":"3167","DOI":"10.1200\/JCO.2009.26.7609","volume":"28","author":"JR Brahmer","year":"2010","unstructured":"Brahmer JR, Drake CG, Wollner I, Powderly JD, Picus J, Sharfman WH et al (2010) Phase I study of single-agent anti-programmed death-1 (MDX-1106) in refractory solid tumors: safety, clinical activity, pharmacodynamics, and immunologic correlates. J Clin Oncol 28(19):3167\u20133175. https:\/\/doi.org\/10.1200\/JCO.2009.26.7609","journal-title":"J Clin Oncol"},{"issue":"12","key":"1575_CR18","doi-asserted-by":"publisher","first-page":"1052","DOI":"10.1002\/onco.13931","volume":"26","author":"R Pathak","year":"2021","unstructured":"Pathak R, Katel A, Massarelli E, Villaflor VM, Sun V, Salgia R (2021) Immune checkpoint inhibitor-induced myocarditis with myositis\/myasthenia gravis overlap syndrome: a systematic review of cases. Oncologist 26(12):1052\u20131061. https:\/\/doi.org\/10.1002\/onco.13931","journal-title":"Oncologist"},{"issue":"7","key":"1575_CR19","doi-asserted-by":"publisher","first-page":"1243","DOI":"10.3390\/diagnostics13071243","volume":"13","author":"L Zotova","year":"2023","unstructured":"Zotova L (2023) Immune checkpoint inhibitors-related myocarditis: a review of reported clinical cases. Diagnostics 13(7):1243. https:\/\/doi.org\/10.3390\/diagnostics13071243","journal-title":"Diagnostics"},{"issue":"11","key":"1575_CR20","doi-asserted-by":"publisher","first-page":"1392","DOI":"10.5858\/arpa.2019-0447-OA","volume":"144","author":"I Sobol","year":"2020","unstructured":"Sobol I, Chen CL, Mahmood SS, Borczuk AC (2020) Histopathologic characterization of myocarditis associated with immune checkpoint inhibitor therapy. Arch Pathol Lab Med 144(11):1392\u20131396. https:\/\/doi.org\/10.5858\/arpa.2019-0447-OA","journal-title":"Arch Pathol Lab Med"},{"issue":"6","key":"1575_CR21","doi-asserted-by":"publisher","first-page":"443","DOI":"10.1093\/intimm\/dxq026","volume":"22","author":"J Wang","year":"2010","unstructured":"Wang J, Okazaki IM, Yoshida T, Chikuma S, Kato Y, Nakaki F, Hiai H, Honjo T, Okazaki T (2010) PD-1 deficiency results in the development of fatal myocarditis in MRL mice. Int Immunol 22(6):443\u2013452. https:\/\/doi.org\/10.1093\/intimm\/dxq026","journal-title":"Int Immunol"},{"issue":"5502","key":"1575_CR22","doi-asserted-by":"publisher","first-page":"319","DOI":"10.1126\/science.291.5502.319","volume":"291","author":"H Nishimura","year":"2001","unstructured":"Nishimura H, Okazaki T, Tanaka Y, Nakatani K, Hara M, Matsumori A et al (2001) Autoimmune dilated cardiomyopathy in PD-1 receptor-deficient mice. Science 291(5502):319\u2013322. https:\/\/doi.org\/10.1126\/science.291.5502.319","journal-title":"Science"},{"issue":"12","key":"1575_CR23","doi-asserted-by":"publisher","first-page":"1477","DOI":"10.1038\/nm955","volume":"9","author":"T Okazaki","year":"2003","unstructured":"Okazaki T, Tanaka Y, Nishio R, Mitsuiye T, Mizoguchi A, Wang J et al (2003) Autoantibodies against cardiac troponin I are responsible for dilated cardiomyopathy in PD-1-deficient mice. Nat Med 9(12):1477\u20131483. https:\/\/doi.org\/10.1038\/nm955","journal-title":"Nat Med"},{"issue":"10","key":"1575_CR24","doi-asserted-by":"publisher","first-page":"4876","DOI":"10.4049\/jimmunol.1200389","volume":"188","author":"ML Tarrio","year":"2012","unstructured":"Tarrio ML, Grabie N, Bu DX, Sharpe AH, Lichtman AH (2012) PD-1 protects against inflammation and myocyte damage in T cell-mediated myocarditis. J Immunol 188(10):4876\u20134884. https:\/\/doi.org\/10.4049\/jimmunol.1200389","journal-title":"J Immunol"},{"issue":"18","key":"1575_CR25","doi-asserted-by":"publisher","first-page":"2062","DOI":"10.1161\/CIRCULATIONAHA.107.709360","volume":"116","author":"N Grabie","year":"2007","unstructured":"Grabie N, Gotsman I, DaCosta R, Pang H, Stavrakis G, Butte MJ et al (2007) Endothelial programmed death-1 ligand 1 (PD-L1) regulates CD8+ T-cell mediated injury in the heart. Circulation 116(18):2062\u20132071. https:\/\/doi.org\/10.1161\/CIRCULATIONAHA.107.709360","journal-title":"Circulation"},{"issue":"4","key":"1575_CR26","doi-asserted-by":"publisher","first-page":"387","DOI":"10.6004\/jnccn.2022.0020","volume":"20","author":"JA Thompson","year":"2022","unstructured":"Thompson JA, Schneider BJ, Brahmer J, Achufusi A, Armand P, Berkenstock MK et al (2022) Management of immunotherapy-related toxicities, version 1.2022, NCCN clinical practice guidelines in oncology. J Natl Compr Canc Netw 20(4):387\u2013405. https:\/\/doi.org\/10.6004\/jnccn.2022.0020","journal-title":"J Natl Compr Canc Netw"},{"issue":"17","key":"1575_CR27","doi-asserted-by":"publisher","first-page":"1714","DOI":"10.1200\/JCO.2017.77.6385","volume":"36","author":"JR Brahmer","year":"2018","unstructured":"Brahmer JR, Lacchetti C, Schneider BJ, Atkins MB, Brassil KJ, Caterino JM et al (2018) Management of immune-related adverse events in patients treated with immune checkpoint inhibitor therapy: American Society of Clinical Oncology clinical practice guideline. J Clin Oncol 36(17):1714\u20131768. https:\/\/doi.org\/10.1200\/JCO.2017.77.6385","journal-title":"J Clin Oncol"},{"issue":"8","key":"1575_CR28","doi-asserted-by":"publisher","first-page":"879","DOI":"10.1634\/theoncologist.2018-0130","volume":"23","author":"S Ganatra","year":"2018","unstructured":"Ganatra S, Neilan TG (2018) Immune checkpoint inhibitor-associated myocarditis. Oncologist 23(8):879\u2013886. https:\/\/doi.org\/10.1634\/theoncologist.2018-0130","journal-title":"Oncologist"},{"issue":"6","key":"1575_CR29","doi-asserted-by":"publisher","first-page":"1544","DOI":"10.1177\/1078155220904152","volume":"26","author":"DH Lee","year":"2020","unstructured":"Lee DH, Armanious M, Huang J, Jeong D, Druta M, Fradley MG (2020) Case of pembrolizumab-induced myocarditis presenting as torsades de pointes with safe re-challenge. J Oncol Pharm Pract 26(6):1544\u20131548. https:\/\/doi.org\/10.1177\/1078155220904152","journal-title":"J Oncol Pharm Pract"},{"key":"1575_CR30","doi-asserted-by":"publisher","first-page":"101374","DOI":"10.1016\/j.gore.2024.101374","volume":"53","author":"SM Glynn","year":"2024","unstructured":"Glynn SM, Gaillard S, Stone RL, Fader AN, Beavis AL (2024) Pembrolizumab with bevacizumab and cyclophosphamide for the treatment of recurrent ovarian clear cell carcinoma: A case series. Gynecol Oncol Rep 53:101374. https:\/\/doi.org\/10.1016\/j.gore.2024.101374","journal-title":"Gynecol Oncol Rep"},{"key":"1575_CR31","doi-asserted-by":"publisher","first-page":"621858","DOI":"10.3389\/fimmu.2021.621858","volume":"12","author":"L Shen","year":"2021","unstructured":"Shen L, Chen H, Wei Q (2021) Immune-therapy-related toxicity events and dramatic remission after a single dose of Pembrolizumab treatment in metastatic thymoma: a case report. Front Immunol 12:621858. https:\/\/doi.org\/10.3389\/fimmu.2021.621858","journal-title":"Front Immunol"}],"container-title":["Investigational New Drugs"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10637-025-01575-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10637-025-01575-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10637-025-01575-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T15:04:00Z","timestamp":1760195040000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10637-025-01575-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8]]},"references-count":31,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2025,8]]}},"alternative-id":["1575"],"URL":"https:\/\/doi.org\/10.1007\/s10637-025-01575-y","relation":{},"ISSN":["0167-6997","1573-0646"],"issn-type":[{"value":"0167-6997","type":"print"},{"value":"1573-0646","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,8]]},"assertion":[{"value":"27 July 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 August 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 August 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of interest"}}]}}